Effect of rituximab in refractory SLE: inhibition of Th1?
Okamoto
H
H
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology; D015536:Down-Regulation; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D000069283:Rituximab; D018417:Th1 Cells / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D019013:CD40 Antigens; D000069283:Rituximab